HeyJaredSteve Duffy
- Indexed articles, last 90 days
- 2
- Latest publication
- Aug 12, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Aug 3, 2026
Latest articles
Glass Particles Prompt Recall of Tyenne Vials (opens the original)
Read excerpt
One lot of Tyenne® (tocilizumab-aazg) Injection 400mg/20mL (20mg/mL)20mL vials has been recalled by Fresenius Kabi after an investigation found glass particles. Tyenne is an interleukin-6 antagonist indicated for the treatment of various rheumatic disorders, chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome, and COVID-19 in certain hospitalized patients. The recalled product involves Lot# 16UI07, NDC# 65219-594-20, and product code 590120, with a
Lipfendra® (enlicitide) to Reduce LDL-C in Adults With Hypercholesterolemia (opens the original)
Read excerpt
Dr Norman Lepor discusses Lipfendra® (enlicitide), a newly approved treatment to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The National Heart Institute’s Director, Dr Norman Lepor, is a Clinical Professor of Medicine at the Geffen School of Medicine at UCLA, an Attending Cardiologist at the Smidt Cedars-Sinai Heart Institute, and Co-director at Cardiovascular Imaging-Westside Medical Imagin
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.